Boehringer Ingelheim To Channel €100 Million Into Shanghai To Expand Production, Strengthen Quality Controls On APIs From China
SHANGHAI - Germany's Boehringer Ingelheim recently announced it would funnel a new €100 million ($ 150 million) investment into China to increase production capacity at its plant in the Shanghai Zhangjiang Hi-Tech Park and to introduce state-of-the-art quality control technology for active pharmaceutical ingredients sourced from China
More from Archive
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.
CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.
A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand
More from Scrip
The highlights of recent comments and insights from industry executives on the key issues covered in Scrip.
Neurocrine reports new details of positive Phase II results in schizophrenia and a favorable safety and cardiovascular profile for its first-in-class oral M4 agonist, now moving to Phase III trials.
Astellas will pay $130m up front for near-global rights to a Phase I/II antibody-drug conjugate that will add to its portfolio of CLDN.18.2-targeted drugs, including Vyloy.